drugset / Trial / NCT06868264

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

NCT06868264

Phase 3 Active not recruiting 880 enrolled Atea Pharmaceuticals, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Timeline

Start
2025-04-07
Primary completion
2026-09
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified Oral
Subject Ruzasvir Other / unclassified Oral
Comparator Sofosbuvir Small molecule Oral
Comparator velpatasvir Other / unclassified Oral